🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2005 Manchester672 Birmingham470 Glasgow437 Cambridge417
All 425 cities
Target enrolment
to
2005 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
By invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398Hemophilia B
CSL Behring
Observational
56
London, Cambridge, Southampton
2023-08-30
Active, closed
Pediatric Patients Aged 1 to 6 Years With APDS
NCT05693129APDS
Pharming Technologies B.V.
Phase 3
16
London
2023-08-30
Recruiting
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
AviadoBio Ltd
Phase 1/2
18
Cambridge, Cardiff, London
2023-08-30
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Ilford, Swinton, London, Aberdeen, Chertsey, Edinburgh, Leeds, Motherwell
2023-08-28
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Recruiting
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
NCT06355934ATTR Amyloidosis
AstraZeneca
Observational
52,121
London
2023-08-21
Active, closed
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 2
41
Glasgow, London
2023-08-16
Active, closed
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
NCT05949645Emphysema or COPD
Apreo Health, Inc.
Not applicable
30
London
2023-08-15
By invitation
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
NCT05844449Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
174
Cardiff, London
2023-08-11
Recruiting
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
NCT05997615Hormone-refractory Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 1
437
London
2023-08-10
Recruiting
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954Malignant Neoplasm of Breast
Novian Health Inc.
Not applicable
122
London, Oxford
2023-08-09
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Recruiting
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312Paroxysmal Nocturnal Hemoglobinuria (PNH)
ADARx Pharmaceuticals, Inc.
Phase 1/2
50
London
2023-08-07
Active, closed
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553SCN2A Encephalopathy, SCN8A Encephalopathy
Praxis Precision Medicines
Phase 2/3
77
Glasgow, London
2023-08-02
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.
Phase 2
220
Barnet, London, Manchester, Nottingham
2023-07-31
Active, closed
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
NCT05949593Geographic Atrophy
Belite Bio, Inc
Phase 3
429
Great Yarmouth, Harrow, London
2023-07-27
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
AbbVie
Phase 3
1,014
Bretton, London, Southampton, Northampton, Londonderry, Luton, Portsmouth
2023-07-25
Active, closed
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
NCT06015841Parkinson Disease, Parkinson Disease 6, Early-Onset
AC Immune SA
Phase 2
150
London, Salford
2023-07-24
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Recruiting
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
NCT04808505Glycogen Storage Disease Type II Infantile Onset
Amicus Therapeutics
Phase 3
36
London
2023-07-18
Recruiting
Lung cAncer Robotic Comparative Study
NCT06038227Lung Cancer
Intuitive Surgical
Observational
600
Bristol, Coventry, London
2023-07-15
Active, closed
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430Hypertension
Mineralys Therapeutics Inc.
Phase 3
1,076
Newquay, Fowey, Glasgow, Chippenham, Cambridge, Carshalton, London, Plymouth
2023-07-14
Active, closed
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
NCT05819866Cerebral Adrenoleukodystrophy (cALD)
Minoryx Therapeutics, S.L.
Phase 3
40
London
2023-07-12
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
AstraZeneca
Phase 1/2
280
Dundee, London, Metropolitan Borough of Wirral, Oxford
2023-07-11
By invitation
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT05697861Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Intellia Therapeutics
Observational
72
London
2023-07-10
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
2023-07-06
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
By invitation
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
NCT05872022Pregnancy, Obesity, Overweight
Novo Nordisk A/S
Observational
728
London
2023-07-05
Recruiting
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
NCT05549258Neuromyelitis Optica Spectrum Disorder
Amgen
Phase 2
15
London, Birmingham
2023-07-03
Active, closed
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
NCT05781113Multiple Sclerosis
Celestra Health Systems
Observational
90
London
2023-07-01
Active, closed
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)
NCT05469789Hereditary Angioedema (HAE)
Takeda
Observational
50
London
2023-06-29
Active, closed
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche
Phase 3
2,000
Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham
2023-06-28
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
OncoC4, Inc.
Phase 3
630
Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester
2023-06-28
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Birmingham, London, Salford
2023-06-27
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
London, Oxford
2023-06-27
Recruiting
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Regeneron Pharmaceuticals
Phase 1/2
36
Cambridge, London
2023-06-27
Active, closed
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05776472Paroxysmal Nocturnal Hemoglobinuria
Swedish Orphan Biovitrum
Observational
165
London
2023-06-26
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
Alumis Inc
Phase 2
408
Leeds, London, Southampton
2023-06-26
Active, closed
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
NCT05601752Ovarian Cancer
USWM CT, LLC
Phase 2
66
London, Manchester
2023-06-26
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
Viatris Innovation GmbH
Phase 3
451
Leicester, London
2023-06-26
Active, closed
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Merck Sharp & Dohme LLC
Phase 1/2
390
London
2023-06-23
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
By invitation
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
NCT05929807Achondroplasia
Ascendis Pharma Growth Disorders A/S
Phase 2/3
140
London
2023-06-21
Active, closed
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
NCT05893498Percutaneous Coronary Intervention
CathWorks Ltd.
Not applicable
1,924
Basildon, London, Taunton
2023-06-21
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
AbbVie
Phase 3
1,328
London, Southampton, Coventry, Leeds, Bristol, Salford
2023-06-21
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 1/2
320
Glasgow, London
2023-06-20
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
NCT05967143Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Sirtex Medical
Observational
845
Manchester, London
2023-06-19
Active, closed
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
290
Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York
2023-06-13
Active, closed
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
NCT05464381Epidermolysis Bullosa
RHEACELL GmbH & Co. KG
Phase 3
91
London
2023-06-13
Active, closed
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942Ulcerative Colitis
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
AbbVie
Phase 1
135
Cambridge, Leicester, London
2023-06-09
Recruiting
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
NCT05897320Episodic Migraine
H. Lundbeck A/S
Phase 3
315
Edinburgh, Great Yarmouth, Glasgow, London
2023-06-08
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
Hoffmann-La Roche
Phase 3
420
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone
2023-06-07
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
AstraZeneca
Phase 1/2
602
Cambridge, Glasgow, Scotland, London, Sutton
2023-06-05
Recruiting
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
NCT05753930Kidney Transplantation in Highly Sensitized Patients
Hansa Biopharma AB
Phase 2
10
London
2023-06-02
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
ArriVent BioPharma, Inc.
Phase 3
398
Guildford, Bebington, London, Manchester, Sutton
2023-06-01
Active, closed
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408Duchenne Muscular Dystrophy
Sarepta Therapeutics, Inc.
Phase 3
148
London, Oxford, Newcastle upon Tyne
2023-05-31
Recruiting
European Aortic Data Collection Project
NCT05896397Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm, Chronic Aortic Dissection
Cook Research Incorporated
Observational
600
Birmingham, Bristol, London
2023-05-31
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
Merck Sharp & Dohme LLC
Phase 2/3
342
London, Newcastle upon Tyne
2023-05-31
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
Amgen
Phase 3
509
London, Manchester
2023-05-31
Active, closed
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
NCT05775848Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
ML Bio Solutions, Inc.
Phase 3
112
London, Newcastle upon Tyne
2023-05-31
Active, closed
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05809531C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis
Apellis Pharmaceuticals, Inc.
Phase 3
100
London, Manchester, Nottingham
2023-05-29
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Recruiting
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
NCT05791864Neuronal Ceroid Lipofuscinosis Type 2
Tern Therapeutics, LLC
Phase 1/2
16
London
2023-05-17
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
240
London, Cardiff, Birmingham, Manchester
2023-05-16
Recruiting
Non-contact Proactive Remote Monitoring of COPD Exacerbations
NCT05598983COPD Exacerbation
Life Detection Technologies
Observational
75
London
2023-05-15
Active, closed
Study of GS-4528 in Adults With Solid Tumors
NCT05840224Solid Tumor
Gilead Sciences
Phase 1
182
London, Sutton
2023-05-11
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
Cardiff, London, Manchester
2023-05-08
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Gilead Sciences
Phase 3
654
London, Manchester, Nottingham
2023-05-08
Active, closed
Bronchoscopic Microwave Ablation of Lung Tissue
NCT05786625Lung Cancer
Creo Medical Limited
Observational
35
London
2023-05-04
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
Summit Therapeutics
Phase 3
420
London, Manchester
2023-05-04
Active, closed
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754Cholangiocarcinoma
Servier Affaires Médicales
Phase 3
299
Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne
2023-05-03
Active, closed
Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease
NCT05755711Coronary Artery Disease
Shockwave Medical, Inc.
Observational
399
Clydebank, Liverpool, London
2023-05-03
Recruiting
Vulvar Disease in Nigeria Observational Study
NCT05890092Vulvar Diseases, Vulvar Atrophy, Dermatoses
KDRS ltd
Observational
1,000
London
2023-05-03
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394Episodic Migraine
AbbVie
Phase 3
450
London, Gillingham, Aberdeen, Stockport
2023-05-01
Recruiting
The Ailliance Post-Market Clinical Study
NCT05856370Spinal Deformity, Spinal Degenerative Disorder, Spinal Fusion Failure, Spinal Trauma
Medtronic Spinal and Biologics
Not applicable
1,000
London
2023-05-01
Active, closed
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Birmingham, Hull, London
2023-04-26
Active, closed
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799Locally Advanced Pancreatic Cancer
OncoSil Medical Limited
Phase 2
88
London, Manchester, Newcastle upon Tyne, Southampton
2023-04-26
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Brighton, Lincoln, London, Londonderry, Newcastle, Newcastle upon Tyne, Plymouth, Worcester
2023-04-25
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca
Phase 2
294
Cambridge, London, Manchester
2023-04-24
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
London, Manchester
2023-04-21
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
Scholar Rock, Inc.
Phase 3
238
Leeds, London, Oxford
2023-04-17
Active, closed
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
NCT07304843Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB
Phase 1/2
84
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
Hoffmann-La Roche
Phase 2
204
London, Preston, Sutton
2023-04-13
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Bristol, Clydebank, Dorchester, Exeter, High Wycombe, Lincoln, London, Sheffield
2023-04-11
Active, closed
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma
NCT05692180Asthma
AstraZeneca
Phase 3
94
London, Manchester
2023-04-05
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
Leeds, London, Manchester
2023-04-04
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
Bayer
Phase 3
985
London, Northwood, Guildford
2023-04-03
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
London, Edinburgh, Sheffield
2023-04-03
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
GlaxoSmithKline
Phase 2
154
Leeds West Yorkshire, London, Sutton
2023-04-03
Recruiting
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
NCT05608681Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc.
Phase 1/2
117
Norwich, Cardiff, Liverpool, London
2023-03-31
Active, closed
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359Parkinson's Disease
Bial R&D Investments, S.A.
Phase 2
237
Dundee, Glasgow, London, Newcastle upon Tyne, Plymouth
2023-03-31
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma
Iovance Biotherapeutics, Inc.
Phase 3
670
Birmingham, Newcastle upon Tyne, Chelsea, Glasgow, London
2023-03-30
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Edinburgh, London, Plymouth, Scunthorpe, Sheffield, Stevenage, Truro
2023-03-23
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632Multiple Myeloma
AbbVie
Phase 1
210
London, Manchester
2023-03-21
Rows per page Showing 1101–1200 of 2005
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=12

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.